Ultragenyx Pharmaceutical (RARE) reported a Q3 net loss late Tuesday of $1.81 per diluted share, widening from a loss of $1.40 a year earlier.

Analysts polled by FactSet expected a loss of $1.23.

Revenue for the quarter ended Sept. 30 was $159.9 million, up from $139.5 million a year earlier.

Analysts surveyed by FactSet expected $166.8 million.

For 2025, the company maintained its revenue guidance of $640 million to $670 million.

Analysts polled by FactSet expect $656.5 million.

Shares of the company were down 11.7% in premarket activity Wednesday.